S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
NASDAQ:PRCT

PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis

$49.39
-1.36 (-2.68%)
(As of 02/28/2024 ET)
Today's Range
$45.20
$52.18
50-Day Range
$40.38
$50.75
52-Week Range
$24.83
$52.32
Volume
1.21 million shs
Average Volume
504,415 shs
Market Capitalization
$2.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.60

PROCEPT BioRobotics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7.7% Downside
$45.60 Price Target
Short Interest
Healthy
8.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of PROCEPT BioRobotics in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$11.86 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.15) to ($1.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.01 out of 5 stars

Medical Sector

823rd out of 958 stocks

Surgical & Medical Instruments Industry

84th out of 91 stocks


PRCT stock logo

About PROCEPT BioRobotics Stock (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

PRCT Stock Price History

PRCT Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Q4 2023 Procept Biorobotics Corp Earnings Call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
PROCEPT BioRobotics: Q4 Earnings Insights
Piper Sandler Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics's Earnings: A Preview
PROCEPT BioRobotics Corporation
Truist Financial Remains a Buy on PROCEPT BioRobotics (PRCT)
PRCT Apr 2024 30.000 put
PRCT Apr 2024 25.000 call
PRCT Feb 2024 47.500 call
PRCT Apr 2024 42.500 call
PRCT Apr 2024 47.500 call
See More Headlines
Receive PRCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
2/28/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PRCT
Fax
N/A
Employees
428
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.60
High Stock Price Target
$58.00
Low Stock Price Target
$37.00
Potential Upside/Downside
-10.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-87,150,000.00
Pretax Margin
-91.56%

Debt

Sales & Book Value

Annual Sales
$75.01 million
Book Value
$4.41 per share

Miscellaneous

Free Float
40,601,000
Market Cap
$2.49 billion
Optionable
Optionable
Beta
1.03
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Reza Zadno Ph.D. (Age 69)
    President, CEO & Director
    Comp: $1.26M
  • Mr. Kevin Waters (Age 47)
    Executive VP & CFO
    Comp: $744.1k
  • Ms. Alaleh Nouri (Age 45)
    EVP, Chief Legal Officer & Corporate Secretary
    Comp: $713.61k
  • Mr. Hisham Shiblaq (Age 48)
    Executive VP & Chief Commercial Officer
    Comp: $757.2k
  • Mr. Mohan F. Sancheti (Age 60)
    Senior Vice President of Operations
  • Mr. Barry Templin
    Executive VP of Technology & Clinical Development
  • Mr. Matthew James Bacso C.F.A.
    Vice President of Investor Relations
  • Ms. Stacey L. Porter (Age 48)
    Chief People Officer
  • Mr. Bijesh Chandran
    Senior Vice President of Regulatory Affairs & Quality Assurance














PRCT Stock Analysis - Frequently Asked Questions

Should I buy or sell PROCEPT BioRobotics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRCT shares.
View PRCT analyst ratings
or view top-rated stocks.

What is PROCEPT BioRobotics' stock price target for 2024?

6 equities research analysts have issued 12-month price objectives for PROCEPT BioRobotics' shares. Their PRCT share price targets range from $37.00 to $58.00. On average, they predict the company's share price to reach $45.60 in the next twelve months. This suggests that the stock has a possible downside of 7.7%.
View analysts price targets for PRCT
or view top-rated stocks among Wall Street analysts.

How have PRCT shares performed in 2024?

PROCEPT BioRobotics' stock was trading at $41.91 on January 1st, 2024. Since then, PRCT shares have increased by 17.8% and is now trading at $49.39.
View the best growth stocks for 2024 here
.

When is PROCEPT BioRobotics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our PRCT earnings forecast
.

How were PROCEPT BioRobotics' earnings last quarter?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.10. The company had revenue of $43.58 million for the quarter, compared to analysts' expectations of $41.79 million. PROCEPT BioRobotics had a negative net margin of 91.56% and a negative trailing twelve-month return on equity of 50.06%. The firm's quarterly revenue was up 83.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.56) EPS.

What ETFs hold PROCEPT BioRobotics' stock?
What guidance has PROCEPT BioRobotics issued on next quarter's earnings?

PROCEPT BioRobotics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $210.0 million-$210.0 million, compared to the consensus revenue estimate of $204.5 million.

When did PROCEPT BioRobotics IPO?

(PRCT) raised $126 million in an initial public offering on Wednesday, September 15th 2021. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share.

Who are PROCEPT BioRobotics' major shareholders?

PROCEPT BioRobotics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.29%), Price T Rowe Associates Inc. MD (2.98%), Price T Rowe Associates Inc. MD (2.98%), Bellevue Group AG (1.75%), Massachusetts Financial Services Co. MA (1.13%) and Point72 Europe London LLP (1.05%). Insiders that own company stock include Alaleh Nouri, Frederic H Moll, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel.
View institutional ownership trends
.

How do I buy shares of PROCEPT BioRobotics?

Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRCT) was last updated on 2/29/2024 by MarketBeat.com Staff